Neuronetics Utdelningar och återköp
Utdelning kriterier kontrolleras 0/6
Neuronetics har inte registrerat sig för att betala utdelning.
Viktig information
n/a
Avkastning på utdelning
-7.0%
Återköpsavkastning
| Total avkastning till aktieägarna | -7.0% |
| Framtida utdelningsavkastning | n/a |
| Utdelningstillväxt | n/a |
| Nästa utbetalningsdag för utdelning | n/a |
| Ex utdelningsdag | n/a |
| Utdelning per aktie | n/a |
| Utdelningsandel | n/a |
Senaste utdelnings- och återköpsuppdateringar
Inga uppdateringar
Recent updates
Uppdatering av berättelse • Sep 10
STIM: Vertically Integrated Mental Health Platform Will Drive Long-Term Upside Potential
Analysts have lifted their fair value estimate for Neuronetics from $3 to $5. They point to the Greenbrook TMS acquisition and the shift toward a vertically integrated mental health platform with 93 company-operated treatment centers as key reasons for the higher price target and what they view as a compelling risk and reward profile.
Uppdatering av berättelse • Aug 27
STIM: Vertically Integrated Interventional Psychiatry Platform Will Support Future Repricing Potential
Analysts have adjusted their fair value estimate for Neuronetics to $6.00 from $5.25, reflecting updated views on the company following its Greenbrook TMS acquisition and the potential they see in its expanded mental health treatment platform. What’s in the News for Neuronetics Neuronetics narrowed its full year 2026 total revenue guidance to a range of US$160 million to US$164 million, compared with the prior range of US$160 million to US$166 million.Analysartikel • Aug 14
US$6.00 - That's What Analysts Think Neuronetics, Inc. (NASDAQ:STIM) Is Worth After These Results
Neuronetics, Inc. ( NASDAQ:STIM ) just released its quarterly report and things are looking bullish. Revenues and...Uppdatering av berättelse • Aug 13
STIM: Vertically Integrated Interventional Psychiatry Platform Will Drive Future Repricing
Analysts lifted their price target on Neuronetics to $5.25 from $4.33, citing the company’s expanded vertically integrated mental health platform following the Greenbrook TMS acquisition and the potential they see in interventional psychiatry adoption. What’s in the News for Neuronetics Neuronetics narrowed full year 2026 total revenue guidance to a range of US$160 million to US$164 million, compared with the prior range of US$160 million to US$166 million.Seeking Alpha • Jul 17
Neuronetics Could Double, But The Balance Sheet May Crack First
Summary Neuronetics, Inc. is rated Hold due to liquidity and dilution risks despite potential undervaluation relative to growth prospects. STIM’s NeuroStar segment offers high-margin, recurring revenue, while Greenbrook clinics provide growth but suffer from low margins and cash burn. Base case valuation approximates the current market price; the bull case offers upside if NeuroStar accelerates growth and Greenbrook clinics reach break-even. Resolution of the March 2027 debt covenant or a price decline below $1 would prompt reconsideration of a long position. Read the full article on Seeking AlphaUppdatering av berättelse • Jun 18
STIM: Policy Shift Allowing Wider TMS Use Will Drive Future Repricing
Analysts kept their Neuronetics price target steady around $4.33, with minor adjustments to the discount rate, profit margin assumptions, and future P/E expectations. These changes reflect updated views on risk and profitability rather than a shift in the core valuation story.Uppdatering av berättelse • Jun 03
STIM: Policy Expansion And Leadership Shift Will Drive Future Repricing
Analysts have trimmed their price target on Neuronetics by $4, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E that, taken together, indicate a more measured outlook for the stock. What's in the News Guidance: Neuronetics issued earnings guidance for full year 2026, projecting total revenue of US$160 million to US$166 million and a gross margin of 47% to 49%.Uppdatering av berättelse • May 01
STIM: Recalibrated Assumptions And Policy Tailwinds Will Drive Future Repricing
Analysts have trimmed their price target on Neuronetics by $4 to reflect updated assumptions on discount rates, profit margins, and future P/E expectations. This results in a slightly lower fair value outlook while keeping the core narrative largely intact.Uppdatering av berättelse • Apr 16
STIM: Reset Expectations And Higher Discount Rate Will Support Future Repricing
Analysts have lowered their price target on Neuronetics by $4, reflecting updated views on the discount rate, profit margin assumptions, and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts view the revised price target as closer to their current assumptions on discount rates and future P/E levels, which they see as a more grounded reflection of Neuronetics' risk profile.Ny berättelse • Apr 04
Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside
Catalysts About Neuronetics Neuronetics develops and operates NeuroStar TMS systems and Greenbrook mental health clinics that provide device based and drug based treatments for depression and other conditions. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 02
STIM: Updated Discount Rate Assumptions Will Support Bullish Repricing Over Time
Analysts have trimmed their price target on Neuronetics by $4 to reflect updated assumptions on discount rates, margins, and future P/E. This has led to a slightly more cautious outlook on the shares.
Ny berättelse • Mar 18
Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade
Catalysts About Neuronetics Neuronetics develops and commercializes NeuroStar TMS systems and operates Greenbrook clinics that provide device based and drug treatments for mental health conditions, including treatment resistant depression. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Mar 18
STIM: Leadership Transition And 2026 Revenue Outlook Will Support Bullish Repricing
Analysts have cut their price target on Neuronetics to $4.33 from $6.50, citing updated assumptions for lower revenue growth at 12.65%, a higher discount rate of 10.04%, a slightly higher profit margin of 13.36%, and a reduced future P/E of 16.22x. What's in the News Neuronetics plans a leadership transition with Dan Reuvers appointed as the next Chief Executive Officer, effective March 23, 2026, while current CEO Keith Sullivan is scheduled to step down on March 23, 2026 and retire on March 31, 2026 after roughly five and a half years leading the company (Key Developments).Analysartikel • Jan 07
There's No Escaping Neuronetics, Inc.'s (NASDAQ:STIM) Muted Revenues Despite A 25% Share Price Rise
Neuronetics, Inc. ( NASDAQ:STIM ) shareholders are no doubt pleased to see that the share price has bounced 25% in the...Analysartikel • Dec 13
Would Neuronetics (NASDAQ:STIM) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Nov 14
Slammed 29% Neuronetics, Inc. (NASDAQ:STIM) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Neuronetics, Inc. ( NASDAQ:STIM ) shares are down a considerable 29% in the last...Analysartikel • Nov 06
The Neuronetics, Inc. (NASDAQ:STIM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Neuronetics, Inc. ( NASDAQ:STIM ) last week reported its latest third-quarter results, which makes it a good time for...Analysartikel • Aug 26
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 29% Lower
Neuronetics, Inc. ( NASDAQ:STIM ) shares have had a horrible month, losing 29% after a relatively good period...Analysartikel • Aug 07
Here's What Analysts Are Forecasting For Neuronetics, Inc. (NASDAQ:STIM) After Its Second-Quarter Results
NasdaqGM:STIM 1 Year Share Price vs Fair Value Explore Neuronetics's Fair Values from the Community and select yours...Analysartikel • May 15
Why We Think Neuronetics, Inc.'s (NASDAQ:STIM) CEO Compensation Is Not Excessive At All
Key Insights Neuronetics' Annual General Meeting to take place on 22nd of May Total pay for CEO Keith Sullivan includes...Analysartikel • May 09
Neuronetics, Inc. (NASDAQ:STIM) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a good week for Neuronetics, Inc. ( NASDAQ:STIM ) shareholders, because the company has just released its...Analysartikel • May 04
Neuronetics, Inc.'s (NASDAQ:STIM) 30% Jump Shows Its Popularity With Investors
Neuronetics, Inc. ( NASDAQ:STIM ) shares have continued their recent momentum with a 30% gain in the last month alone...
Ny berättelse • Apr 09
TMS Acquisition And BMP Expansion Will Transform Treatment Delivery
The acquisition of Greenbrook and expansion of the BMP program are expected to significantly boost revenue through increased patient access and operational efficiency.Seeking Alpha • Mar 30
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs
Summary Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth and cash flow positivity by Q3 2025. Despite risks like high volatility and competition, Neuronetics' strong market position and growth potential make it a promising investment. Read the full article on Seeking AlphaAnalysartikel • Mar 06
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 69% Yet They're Still Not Telling The Full Story
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 69% in...Analysartikel • Feb 10
Industry Analysts Just Made A Dazzling Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Revenue Forecasts
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) may be thrilled to learn that the analysts have just delivered a...Analysartikel • Jan 11
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 43% Yet They're Still Not Telling The Full Story
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 43% in...Analysartikel • Jan 02
Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Nov 18
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Market forces rained on the parade of Neuronetics, Inc. ( NASDAQ:STIM ) shareholders today, when the analysts...Analysartikel • Nov 05
A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Those holding Neuronetics, Inc. ( NASDAQ:STIM ) shares would be relieved that the share price has rebounded 28% in the...Analysartikel • Aug 13
Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
The Neuronetics, Inc. ( NASDAQ:STIM ) share price has fared very poorly over the last month, falling by a substantial...Analysartikel • May 24
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
Key Insights Neuronetics will host its Annual General Meeting on 30th of May Total pay for CEO Keith Sullivan includes...Analysartikel • May 09
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) had a terrible week, as shares crashed 28% to US$2.55 in the week...Seeking Alpha • May 09
Neuronetics: Reality Set In
Summary Neuronetics' share price dropped after reporting soft Q1 2024 results, with weak system sales undermining strong treatment demand. Neuronetics' losses remain relatively large, and the company's balance sheet provides it with limited flexibility. The stock may have further to fall if Neuronetics is not able to demonstrate a clear path to profitability in the coming quarters. Read the full article on Seeking AlphaStabilitet och tillväxt i betalningar
Hämta utdelningsdata
Stabil utdelning: Otillräcklig data för att avgöra om STIM s utdelningar per aktie har varit stabila tidigare.
Växande utdelning: Otillräcklig data för att avgöra om STIM s utdelningsbetalningar har ökat.
Utdelningsavkastning jämfört med marknaden
| Neuronetics Utdelningsavkastning jämfört med marknaden |
|---|
| Segment | Utdelningsavkastning |
|---|---|
| Företag (STIM) | n/a |
| Marknadens lägsta 25% (US) | 1.4% |
| Marknad Topp 25% (US) | 4.1% |
| Genomsnitt för branschen (Medical Equipment) | 2.0% |
| Prognosanalytiker (STIM) (upp till 3 år) | n/a |
Anmärkningsvärd utdelning: Det går inte att utvärdera STIM s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Hög utdelning: Det går inte att utvärdera STIM s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Vinstutdelning till aktieägarna
Resultattäckning: Otillräcklig data för att beräkna STIM s utbetalningskvot för att avgöra om dess utdelningar täcks av intäkter.
Kontantutbetalning till aktieägarna
Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom STIM inte har rapporterat några utbetalningar.
Upptäck bolag med stark utdelning
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/14 09:24 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Neuronetics, Inc. bevakas av 5 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Sam Eiber | BTIG |
| William Plovanic | Canaccord Genuity |